Hepatitis C virus

Summary

Alias: hepatitis C virus HCV, human hepatitis C virus, human hepatitis C virus HCV, human hepatitis virus C HCV, post-transfusion hepatitis non A non B virus, HCV, Hepatitis C, human hepatitis virus HCV

Top Publications

  1. Herrera Sánchez D, Castilla Rodríguez J, Castrejón Vázquez M, Vargas Camaño M, Medina Torres E, Blancas Galicia L, et al. [Infection due to Mycobacterium bovis in common variable immunodeficiency]. Rev Alerg Mex. 2015;62:75-82 pubmed
    ..Viral infections caused by herpes zoster, cytomegalovirus (CMV) and hepatitis C are rare...
  2. Naga M, Amin M, Algendy D, Elbadry A, Fawzi M, Foda A, et al. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response. World J Gastroenterol. 2015;21:11141-51 pubmed publisher
    ..polymorphism of the low-density lipoprotein (LDL) receptor with antiviral responses in Egyptian chronic hepatitis C virus (HCV) patients...
  3. Grice I, Mariottini G. Glycans with Antiviral Activity from Marine Organisms. Results Probl Cell Differ. 2018;65:439-475 pubmed publisher
    ..cytomegalovirus, dengue virus, Epstein-Barr virus, encephalomyocarditis virus, human immunodeficiency virus, hepatitis C virus, herpes simplex virus, human cytomegalovirus, human papilloma virus, human rhino virus, influenza virus, ..
  4. Udina M, Navines R, Egmond E, Oriolo G, Langohr K, Gimenez D, et al. Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. Int J Neuropsychopharmacol. 2016;19: pubmed publisher
    ..the impact on mood of initiating IFN-alpha and ribavirin treatment in a cohort of patients with chronic hepatitis C. We investigated clinical, personality, and functional genetic variants associated with cytokine-induced ..
  5. Calderone V, Gallego J, Fernández Miranda G, Garcia Pras E, Maillo C, Berzigotti A, et al. Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease. Gastroenterology. 2016;150:982-97.e30 pubmed publisher
    ..We obtained transjugular liver biopsies from patients with hepatitis C virus-associated cirrhosis or liver tissues removed during transplantation; healthy human liver tissue was ..
  6. Wang C, Wey K, Mo L, Chang K, Lin R, Kuo J. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16:3595-604 pubmed
    ..In the USA, Europe and particularly Japan, hepatitis C virus (HCV) related HCC accounts for most liver cancer, as compared with Asia-Pacific regions, where hepatitis B ..
  7. Lin K, Lin A, Linn S, Reddy M, Bakshi A. Recurrent Primary Suprahepatic Abscess Due to Providencia Stuartii: A Rare Phenomenon. Cureus. 2017;9:e1691 pubmed publisher
    ..B virus (HBV) deoxyribonucleic (DNA) polymerase chain reaction (PCR) showed > 17 million IU/ml and hepatitis C virus (HCV) Ab reactive. A right, upper quadrant sonogram showed 4.1x0.9x2...
  8. Qiu J, Zhou W, Zhou W, Tang X, Yuan Q, Zhu X, et al. The Treatment of Infected Femoral Artery Pseudoaneurysms Secondary to Drug Abuse: 11 Years of Experience at a Single Institution. Ann Vasc Surg. 2016;36:35-43 pubmed publisher
    ..Seventy-four patients presented with anemia and 75 patients presented with hypoproteinemia. Hepatitis B, hepatitis C, syphilis, and HIV were found in 42, 57, 12, and 2 patients, respectively. One patient gave up the treatment...
  9. Tedesco D, Thapa M, Chin C, Ge Y, Gong M, Li J, et al. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic ?? T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease. Gastroenterology. 2018;154:2178-2193 pubmed publisher
    ..tissues from 10 patients undergoing liver transplantation for primary sclerosing cholangitis or chronic hepatitis C virus infection. Tissues were analyzed for cytokine production by ?? TCR+ cells...

More Information

Publications399 found, 100 shown here

  1. Begolli Gerqari A, Ferizi M, Kotori M, Daka A, Hapciu S, Begolli I, et al. Activation of Herpes Simplex Infection after Tattoo. Acta Dermatovenerol Croat. 2018;26:75-76 pubmed
    ..as granulomas, allergic reactions, Koebner phenomenon, lupus erythematosus, psoriasis, lichen ruber planus, hepatitis C, and HIV infections should also be considered as potential consequences of tattooing (3-7)...
  2. Basseri R, Schmidt M, Basseri B. Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection: a case report and review of literature. Clin J Gastroenterol. 2010;3:237-42 pubmed publisher
    The hepatitis C virus (HCV) is the most common blood-borne pathogen and currently infects over two hundred and fifty million individuals worldwide...
  3. Kohjima M, Yoshimoto T, Enjoji M, Fukushima N, Fukuizumi K, Nakamura T, et al. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. World J Gastroenterol. 2015;21:3291-9 pubmed publisher
    ..Iron overload is associated with liver damage by increasing oxidative stress and hepatitis C virus (HCV) is reported to induce iron accumulation in hepatocytes in vivo...
  4. Leblebicioglu H, Arends J, Ozaras R, Corti G, Santos L, Boesecke C, et al. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res. 2018;150:9-14 pubmed publisher
    ..agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection...
  5. Koo J, Lee H, Kim W, Kim S. Endoplasmic Reticulum Stress in Hepatic Stellate Cells Promotes Liver Fibrosis via PERK-Mediated Degradation of HNRNPA1 and Up-regulation of SMAD2. Gastroenterology. 2016;150:181-193.e8 pubmed publisher
    ..RNAs were measured in 2 sets of liver samples (n = 25 and n = 44) collected from patients with chronic hepatitis C virus infection and/or fibrosis. ER stress was induced in cells and mice using chemical agents...
  6. Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, et al. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Gastroenterology. 2017;152:1383-1394 pubmed publisher
    There is still a risk for hepatocellular carcinoma (HCC) development after eradication of hepatitis C virus (HCV) infection with antiviral agents...
  7. Kozajda A. [Biological agents intentionally used in Poland based on data from the National Register Of Biological Agents]. Med Pr. 2018;69:413-424 pubmed publisher
    ..on Cancer as carcinogenic were used (viruses: hepatitis B virus (HBV) - 10 enterprises and 257 workers, hepatitis C virus (HCV) - 10 enterprises and 232 workers, Epstein-Barr virus (EBV) - 9 enterprises and 227 workers, human ..
  8. Raj R, Bhatti J, Badada S, Ramteke P. Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM). Diabetes Metab Res Rev. 2015;31:663-71 pubmed publisher
    ..Cell organelles, hepatitis C-virus infection, reactive oxygen species produced in mitochondria, and defective insulin signaling due to the ..
  9. Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie S, Horne A. The role of infection in miscarriage. Hum Reprod Update. 2016;22:116-33 pubmed publisher
    ..Q fever, adeno-associated virus, Bocavirus, Hepatitis C and Mycoplasma genitalium infections do not appear to affect pregnancy outcome...
  10. Tovey M, Lallemand C. Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel). 2010;3:1162-1186 pubmed
    ..signaling molecules are associated with IFN-induced neutropenia and thrombocytopenia in patients with chronic hepatitis C. IFN? binds to a cell-surface receptor composed of two transmembrane polypeptides IFGR1 and IFGR2 resulting in ..
  11. Chang M, Cheng M, Chang S, Tang H, Chiu C, Yeh C, et al. Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity. Amino Acids. 2017;49:291-302 pubmed publisher
    ..implications in chronic hepatitis C (CHC) patients with sustained virological response (SVR) following anti-hepatitis C virus (HCV) therapy remains elusive. A prospective cohort study was conducted on 222 CHC patients with SVR...
  12. Kazakos E, Kountouras J, Polyzos S, Deretzi G. Novel aspects of defensins' involvement in virus-induced autoimmunity in the central nervous system. Med Hypotheses. 2017;102:33-36 pubmed publisher
    ..During human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, selective elicitation of the VH1-69 antibody subfamily directed against specific, viral ..
  13. McCarthy E, Vakos A, Cottagiri M, Mantila J, Santhanam L, Thomas D, et al. Identification of a Shared Cytochrome p4502E1 Epitope Found in Anesthetic Drug-Induced and Viral Hepatitis. mSphere. 2018;3: pubmed publisher
    Cytochrome p4502E1 (CYP2E1) autoantibodies are biomarkers for drug-induced hepatitis and chronic hepatitis C. However, major histocompatibility-restricted CYP2E1 epitopes associated with these diseases have not been identified...
  14. Kapoor A, Simmonds P, Scheel T, Hjelle B, Cullen J, Burbelo P, et al. Identification of rodent homologs of hepatitis C virus and pegiviruses. MBio. 2013;4:e00216-13 pubmed publisher
    b>Hepatitis C virus (HCV) and human pegivirus (HPgV or GB virus C) are globally distributed and infect 2 to 5% of the human population...
  15. Qureshi A, Zuvanich E, Khan D, Mushtaq S, Silswal N, Qureshi N. Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs. Lipids Health Dis. 2018;17:62 pubmed publisher
    ..subunits (X, Y, Z, LMP7, LMP2, LMP10), ICAM-1, VCAM-1, and TNF-? using total RNAs derived from plasmas of hepatitis C patients was investigated...
  16. Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis. 2013;13:203 pubmed publisher
    ..Effects of Hepatitis C (HCV) co-infection and relationships between altered lipid metabolites and markers of inflammation, microbial ..
  17. Kerkar N, Yanni G. 'De novo' and 'recurrent' autoimmune hepatitis after liver transplantation: A comprehensive review. J Autoimmun. 2016;66:17-24 pubmed publisher
    ..In adults, hepatitis C (HCV) is the most common indication for LT and HCV often recurs after LT, requiring treatment with Interferon ..
  18. Menon R, Badri P, Wang T, Polepally A, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63:20-9 pubmed publisher
    ..ombitasvir (OBV), and dasabuvir (DSV) are direct-acting antiviral agents (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection...
  19. Pattabhi S, Wilkins C, Dong R, Knoll M, Posakony J, Kaiser S, et al. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol. 2015;90:2372-87 pubmed publisher
    ..that were infected with viruses of the family Flaviviridae, including West Nile virus, dengue virus, and hepatitis C virus, as well as viruses of the families Filoviridae (Ebola virus), Orthomyxoviridae (influenza A virus), ..
  20. Bulatova I, Shchekotova A, Krivtsov A, Shchekotov V, Nasibullina N, Suzdal tseva K, et al. [Metabolic disorder and polymorphism of the genes encoding for beta-2-adrenergic receptor and apolipoproteins B in chronic hepatitis C and non-alcoholic fatty liver diseases]. Klin Med (Mosk). 2015;93:35-41 pubmed
    ..beta-2-adrenergic receptor (ADRB2 (rs1042713) and apolipoproteins B (ApoB(rs5742904) in patients with chronic hepatitis C (CHC) depending on virus genotype and in patients with non-alcoholic fatty liver diseases (NAFLD) and ..
  21. Shin H, Shin A, Woo H, Fox K, Walsh N, Lo Y, et al. Prevention of infection-related cancers in the WHO Western Pacific Region. Jpn J Clin Oncol. 2016;46:13-22 pubmed publisher
    ..with human papilloma virus, Helicobacter pylori, human immunodeficiency virus-I, hepatitis B virus and hepatitis C virus and liver flukes...
  22. Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016;51:629-50 pubmed publisher
    ..combination therapy improve the prognosis of patients with hepatitis B virus related liver cirrhosis and hepatitis C related compensated liver cirrhosis, respectively, although the latter therapy may be replaced by direct-acting ..
  23. Shiferaw F, Letebo M, Bane A. Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia. BMC Public Health. 2016;16:769 pubmed publisher
    ..In Ethiopia, Hepatitis B is endemic with an average prevalence of 10.8 %, and the prevalence of Hepatitis C is 2 %...
  24. Abdel Razik A, Mousa N, Abdel Aziz M, Elhelaly R, Elzehery R, Zalata K, et al. Elevated serum α-fetoprotein levels in patients with chronic hepatitis C virus genotype 4: not the end of the story. Eur J Gastroenterol Hepatol. 2016;28:313-22 pubmed publisher
    ..histological characteristics, and biochemical markers associated with increased serum AFP levels in hepatitis C virus genotype 4-infected patients with no evidence of hepatocellular carcinoma and to determine the effect of ..
  25. Yang J, Mohamed E, Aziz A, Shousha H, Hashem M, Nabeel M, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2:103-111 pubmed publisher
    ..b>Hepatitis C virus was the leading cause of hepatocellular carcinoma in Egypt (1054 [84%] of 1251 patients), and hepatitis B ..
  26. Siu G, Zhou F, Yu M, Zhang L, Wang T, Liang Y, et al. Hepatitis C virus NS5A protein cooperates with phosphatidylinositol 4-kinase IIIα to induce mitochondrial fragmentation. Sci Rep. 2016;6:23464 pubmed publisher
    b>Hepatitis C virus (HCV) has long been observed to take advantage of the host mitochondria to support viral replication and assembly. The HCV core protein has been implicated to fragment host mitochondria...
  27. Vitrenko Y, Kostenko I, Kulebyakina K, Sorochynska K. Prevalence of human pegivirus-1 and sequence variability of its E2 glycoprotein estimated from screening donors of fetal stem cell-containing material. Virol J. 2017;14:167 pubmed publisher
    ..of the Flaviviridae family whose genomic organization and mode of cellular entry is similar to that of hepatitis C virus (HCV)...
  28. Traebert J, Nickel D, Traebert E, Escalante J, Schneider I. The burden of infectious diseases in the Brazilian Southern state of Santa Catarina. J Infect Public Health. 2016;9:181-91 pubmed publisher
    ..An ecological study was conducted. The infectious diseases included were HIV/AIDS, tuberculosis, hepatitis B, hepatitis C, Chagas disease, diarrheal diseases and other infectious diseases...
  29. Emery J, Feld J. Treatment of hepatitis B virus with combination therapy now and in the future. Best Pract Res Clin Gastroenterol. 2017;31:347-355 pubmed publisher
    ..Building on the success seen in the treatment of hepatitis C (HCV) and human immunodeficiency virus (HIV), combination therapy may be an essential strategy to improve ..
  30. Shiffman M, Morishima C, Dienstag J, Lindsay K, Hoefs J, Lee W, et al. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009;137:1986-94 pubmed publisher
    The Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) trial demonstrated that low-dose peginterferon maintenance therapy was ineffective in preventing clinical outcomes in patients with chronic hepatitis C, advanced ..
  31. Fontana R, Sanyal A, Ghany M, Lee W, Reid A, Naishadham D, et al. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology. 2010;138:2321-31, 2331.e1-2 pubmed publisher
    ..of de novo gastroesophageal variceal formation and progression in a large cohort of patients with chronic hepatitis C and advanced fibrosis...
  32. Abu Dayyeh B, Yang M, Dienstag J, Chung R. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig Dis Sci. 2011;56:564-8 pubmed publisher
    ..In the HALT-C Trial, subjects with chronic hepatitis C and advanced hepatic fibrosis (Ishak stage ≥3) underwent serial liver biopsies at baseline, 1...
  33. Donnelly R, Dickensheets H, O Brien T. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 2011;32:443-50 pubmed publisher
    Interferon (IFN)-α, a type-I IFN, is widely used to treat chronic hepatitis C virus infection, but the broad expression of IFN-α receptors often leads to adverse reactions in many organs...
  34. Pavan M, Pavin E, Goncales F, Zantut Wittmann D, Wittmann D. Virus C genotype predisposes to primary hypothyroidism during interferon-? treatment for chronic hepatitis C. Braz J Infect Dis. 2011;15:449-56 pubmed
    The treatment of the chronic hepatitis C (HCV) with ?-interferon is associated with thyroid dysfunction (TD)...
  35. Morishima C, Shiffman M, Dienstag J, Lindsay K, Szabo G, Everson G, et al. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012;107:1388-98 pubmed publisher
    ..serum alanine aminotransferase level, fibrosis progression and clinical outcomes after randomization, and hepatitis C virus (HCV) RNA decline before and after randomization were evaluated...
  36. Switzer W, Shankar A, Trimble S, Thompson A, Giardina P, Cohen A, et al. Human T cell lymphotropic virus type 1 infection among U.S. thalassemia patients. AIDS Res Hum Retroviruses. 2013;29:1006-9 pubmed publisher
    ..Demographic information and clinical information were collected at study enrollment, including HIV and hepatitis C virus (HCV) status. Three patients (1...
  37. Howell J, Sawhney R, Skinner N, Gow P, Angus P, Ratnam D, et al. Toll-like receptor 3 and 7/8 function is impaired in hepatitis C rapid fibrosis progression post-liver transplantation. Am J Transplant. 2013;13:943-953 pubmed publisher
    Recurrence of hepatitis C (HCV) postliver transplant is universal, with a subgroup developing rapid hepatic fibrosis...
  38. Araújo S, Bañón S, Machuca I, Moreno A, Pérez Elías M, Casado J. Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs. Eur J Endocrinol. 2014;171:545-54 pubmed publisher
    ..Incident DM was assessed during the follow-up. First-line patients had a short time of HIV infection, less hepatitis C virus coinfection, and received mainly an efavirenz-based regimen...
  39. Lam A, Edwards T, Mosley R, Murakami E, Bansal S, Lugo C, et al. Molecular and structural basis for the roles of hepatitis C virus polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistance. Antimicrob Agents Chemother. 2014;58:6861-9 pubmed publisher
    Resistance to the 2'-F-2'-C-methylguanosine monophosphate nucleotide hepatitis C virus (HCV) inhibitors PSI-352938 and PSI-353661 was associated with a combination of amino acid changes (changes of S to G at position 15 [S15G], C223H, ..
  40. Salama M, Sabry D, Al Ghussein M, Ahmed R, AbdAllah S, Taha F, et al. Molecular detection of monocyte chemotactic protein-1 polymorphism in spontaneous bacterial peritonitis patients. World J Gastroenterol. 2014;20:11793-9 pubmed publisher
    ..Fifty patients with post-hepatitis C liver cirrhosis and ascites were categorized into two groups; group I included 25 patients with SBP and group ..
  41. Spaan M, Kreefft K, de Graav G, Brouwer W, de Knegt R, ten Kate F, et al. CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses. J Hepatol. 2015;62:303-10 pubmed publisher
    During chronic HCV infection, T cell dependent virus-specific antibodies are produced. However, the role of B-T cell interaction in chronic HCV is largely unknown...
  42. Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, et al. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production. Gastroenterology. 2015;148:403-14.e7 pubmed publisher
    Cyclophilins are host factors required for hepatitis C virus replication. Cyclophilin inhibitors such as alisporivir have shown strong anti-hepatitis C virus activity in vitro and in clinical studies...
  43. Renner I, Funk N, Geissler R, Friedrich S, Penzel A, Behrens S. Antiviral interferon-beta signaling induced by designed transcription activator-like effectors (TALE). PLoS ONE. 2014;9:e114288 pubmed publisher
    ..of pathogen pattern recognition but effectively prohibits viral RNA replication as demonstrated with a hepatitis C virus replicon...
  44. Cusato J, Allegra S, De Nicolò A, Boglione L, Fatiguso G, Cariti G, et al. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. Biomed Pharmacother. 2015;69:63-9 pubmed publisher
    ..Twenty-nine HCV-1 patients treated with telaprevir, ribavirin and pegylated-interferon-α were retrospectively analyzed; allelic ..
  45. Pascutti M, Geerman S, Slot E, van Gisbergen K, Boon L, Arens R, et al. Enhanced CD8 T cell responses through GITR-mediated costimulation resolve chronic viral infection. PLoS Pathog. 2015;11:e1004675 pubmed publisher
    ..As such, increasing costimulation through GITR may be an attractive strategy to increase anti-viral CTL responses without exacerbating pathology, in particular to persistent viruses such as HIV and HCV.
  46. Meyer K, Kwon Y, Liu S, Hagedorn C, Ray R, Ray R. Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Sci Rep. 2015;5:9012 pubmed publisher
    ..Interferon (IFN) and the IFN-stimulated genes (ISGs) play a central role in antiviral responses against hepatitis C virus (HCV) infection...
  47. Rabasseda X. A report from the European Association for the Study of the Liver's 50th International Liver Congress (April 22-26 - Vienna, Austria). Drugs Today (Barc). 2015;51:261-71 pubmed publisher
    ..Echoing epidemiological facts and a high social interest for hepatitis C virus infection, new findings with investigational and potential new therapies for the disease centered much of ..
  48. Merchant R, Delong A, Liu T, Baird J. Factors Influencing Uptake of Rapid HIV and Hepatitis C Screening Among Drug Misusing Adult Emergency Department Patients: Implications for Future HIV/HCV Screening Interventions. AIDS Behav. 2015;19:2025-35 pubmed publisher
    ..department (ED) patients, we determined if a tailored brief intervention (BI) increased uptake of rapid HIV/HCV screening, and identified factors associated with greater screening uptake...
  49. Kamran S, Calmus Y, Pomey M, Vidal Trécan G. What Kind of Information About Marginal Donors Is Available Through Sources Other Than Health Care Professionals for Patients on the Waiting List for Organ Transplantation?. Interact J Med Res. 2015;4:e15 pubmed publisher
    ..In France, physicians are not required to provide information to recipients about marginal donors except for hepatitis C or hepatitis B infection and non-heart-beating donations...
  50. Hsu C, Hsu S, Chen H, Liu C, Jeng J, Liu C, et al. Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. Hepatol Int. 2013;7:171-9 pubmed publisher
    ..are highly integrated, metabolic profiles may play an important role in the link between IL28B genotypes and hepatitis C virus (HCV) infection...
  51. Qu Y, Li T, Wang L, Liu F, Ye Q. Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis. Clin Res Hepatol Gastroenterol. 2016;40:203-12 pubmed publisher
    ..Eligible studies should evaluate simeprevir plus peginterferon and ribavirin combination therapy for chronic hepatitis C genotype 1 patients, while the standard peginterferon and ribavirin therapy as control group...
  52. Sulkowski M, Vargas H, Di Bisceglie A, Kuo A, Reddy K, Lim J, et al. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. 2016;150:419-29 pubmed publisher
    ..regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial...
  53. Ghazaryan L, Smith L, Parker M, Flanigan C, Pulver W, Sullivan T, et al. Hepatitis C Seroprevalence Among HIV-Infected Childbearing Women in New York State in 2006. Matern Child Health J. 2016;20:550-5 pubmed publisher
    To identify factors associated with maternal hepatitis C virus (HCV) seroprevalence and transmission of HCV as identified by qualitative HCV ribonucleic acid (RNA) in the infants of human immunodeficiency virus (HIV) infected women ..
  54. Derbala M, Elbadri M, Amer A, Alkaabi S, Sultan K, Kamel Y, et al. Aspartate transaminase to platelet ratio index in hepatitis C virus and Schistosomiasis coinfection. World J Gastroenterol. 2015;21:13132-9 pubmed publisher
    ..ratio index (APRI) alone and with antischistosomal antibody (Ab) in patients with hepatitis C virus (HCV) and schistosomiasis coinfection...
  55. Branche E, Conzelmann S, Parisot C, Bedert L, Lévy P, Bartosch B, et al. Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein. PLoS ONE. 2016;11:e0146000 pubmed publisher
    The hepatitis C virus (HCV) life cycle is closely associated with lipid metabolism. In particular, HCV assembly initiates at the surface of lipid droplets...
  56. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797-808 pubmed publisher
    At global level, there are 37 million people infected with HIV and 115 million people with antibodies to hepatitis C virus (HCV). Little is known about the extent of HIV-HCV co-infection...
  57. Wijarnpreecha K, Thongprayoon C, Sanguankeo A, Upala S, Ungprasert P, Cheungpasitporn W. Hepatitis C infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:39-45 pubmed publisher
    b>Hepatitis C virus (HCV) infection is a major cause of cirrhosis worldwide...
  58. Arora S, Young S, Kodali S, Singal A. Hepatic porphyria: A narrative review. Indian J Gastroenterol. 2016;35:405-418 pubmed
    ..is frequently associated with a combination of multiple susceptibility factors such as alcohol use, smoking, hepatitis C virus infection, HIV infection, estrogen use, and mutations of the hemochromatosis gene...
  59. Chen C, Huang J, Wang C, Tahara S, Zhou L, Kondo Y, et al. Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nat Commun. 2017;8:13882 pubmed publisher
    B-cell infection by hepatitis C virus (HCV) has been a controversial topic...
  60. Kersten S, Stienstra R. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie. 2017;136:75-84 pubmed publisher
    ..of PPARA in human liver is reduced in patients with non-alcoholic steatohepatitis or infected with the hepatitis C virus. 3) PPAR? in human liver is able to effectively induce the expression of numerous genes involved in numerous ..
  61. Cornberg M, Petersen J, Schober A, Mauss S, Böker K, Link R, et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2017;45:688-700 pubmed publisher
    Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes. Since 2014, several new treatment regimens have been approved but sometimes based on limited data.
  62. Youssef N, El Kassas M, Farag A, Shepherd A. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt. BMC Gastroenterol. 2017;17:18 pubmed publisher
    ..to (1) assess the PROs (health-related quality of life (HRQoL), mental health and perceived social support) of HCV patients receiving DAAs therapy prior, during and at the end of therapy; (2) evaluate PROs of Interferon-free (dual)..
  63. Falcon V, Acosta Rivero N, Gonzalez S, Duenas Carrera S, Martinez Donato G, Menendez I, et al. Ultrastructural and biochemical basis for hepatitis C virus morphogenesis. Virus Genes. 2017;53:151-164 pubmed publisher
    Chronic infection with HCV is a leading cause of cirrhosis, hepatocellular carcinoma and liver failure. One of the least understood steps in the HCV life cycle is the morphogenesis of new viral particles...
  64. Vavassori A, Lanza P, Izzo I, Casari S, Odolini S, Zaltron S, et al. [Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]. Recenti Prog Med. 2017;108:98-100 pubmed publisher
    New Direct-acting Antiviral Agents (DAA)-based anti-HCV therapies currently provide extraordinary opportunities to cure patients. Drug-drug interactions are however a real challenge during treatment...
  65. Uitte de Willige S, Keane F, Bowen D, Malfliet J, Zhang H, Maneck B, et al. Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. PLoS ONE. 2017;12:e0178987 pubmed publisher
    ..In plasma of 465 control individuals, 368 patients with coronary heart disease (CHD) and 102 hepatitis C virus (HCV) infected patients with severe liver disease before and after liver transplant, cFAP activity levels ..
  66. Duan J, Wang Y, Liu D, Ma J. Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature. Ocul Immunol Inflamm. 2017;:1-6 pubmed publisher
    To describe a case of Vogt-Koyanagi-Harada disease (VKH) presenting in a hepatitis C patient after interferon-alpha (IFN-?) and ribavirin treatment.
  67. Bennett F, Buevich A, Huang H, Girijavallabhan V, Kerekes A, Huang Y, et al. Concise syntheses and HCV NS5B polymerase inhibition of (2'R)-3 and (2'S)-2'-ethynyluridine-10 and related nucleosides. Bioorg Med Chem Lett. 2017;27:5349-5352 pubmed publisher
    ..To evaluate their effectiveness against HCV NS5B polymerase, the nucleosides were converted to their respective 5'-O-triphosphates...
  68. Desombere I, Mesalam A, Urbanowicz R, Van Houtte F, Verhoye L, Keck Z, et al. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. Antiviral Res. 2017;148:53-64 pubmed publisher
    Infections with hepatitis C virus (HCV) represent a worldwide health burden and a prophylactic vaccine is still not available. Liver transplantation (LT) is often the only option for patients with HCV-induced end-stage liver disease...
  69. Bizid S, Blili S, Mlika R, Haj Said A, Korri Youssoufi H. Direct Electrochemical DNA Sensor based on a new redox oligomer modified with ferrocene and carboxylic acid: Application to the detection of Mycobacterium tuberculosis mutant strain. Anal Chim Acta. 2017;994:10-18 pubmed publisher
    ..DNA sensing and for this purpose the acid functional group of Fc-acid-OMPA was attached with the DNA probe of hepatitis C bearing amino group in 5' position through amid link...
  70. Abdel Hameed E, Rouster S, Boyce C, Zhang X, Biesiada J, Medvedovic M, et al. Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients. Dig Dis Sci. 2018;63:645-652 pubmed publisher
    The prevalence of naturally occurring HCV-NS5A resistance-associated substitutions (RAS) to DAA drugs might affect the response to treatment in HCV/HIV coinfected subjects...
  71. Chen C, Lin C, Kao C. Association between Inflammatory Bowel Disease and Cholelithiasis: A Nationwide Population-Based Cohort Study. Int J Environ Res Public Health. 2018;15: pubmed publisher
    ..liver cirrhosis, hypertension, chronic obstructive pulmonary disease, stroke, coronary artery disease, and hepatitis C virus infection. However, UC was related to the development of GSD (aHR = 1.44, 95% CI = 1.19-1...
  72. Lucas M, Deshpande P, James I, Rauch A, Pfafferott K, Gaylard E, et al. Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome. Sci Rep. 2018;8:7224 pubmed publisher
    b>Hepatitis C virus (HCV)-specific T cell responses are critical for immune control of infection...
  73. Humes D, Ramírez S, Jensen T, Li Y, Gottwein J, Bukh J. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology. 2018;522:177-192 pubmed publisher
    The six major epidemiologically important hepatitis C virus (HCV) genotypes differ in global distribution and antiviral responses...
  74. Hagiya H, Miyake T, Kokumai Y, Murase T, Kuroe Y, Nojima H, et al. Co-infection with invasive pulmonary aspergillosis and Pneumocystis jirovecii pneumonia after corticosteroid therapy. J Infect Chemother. 2013;19:342-7 pubmed publisher
    A 95-year-old man with chronic obstructive pulmonary disease and chronic hepatitis C virus infection was treated for acute lung injury caused by Chlamydophila pneumoniae with antibiotics and high-dose corticosteroids...
  75. Velazquez V, Uebelhoer L, Thapa M, Ibegbu C, Courtney C, Bosinger S, et al. Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. Hepatology. 2015;61:843-56 pubmed publisher
    ..Liver CD34 frequencies were reduced during nonalcoholic steatohepatitis (NASH) and chronic hepatitis C virus (HCV) compared to alcohol liver disease (ALD), and this reduction correlated with viral load in the HCV ..
  76. Giroux S, Bilimoria D, Cadilhac C, Cottrell K, Denis F, Dietrich E, et al. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b. Bioorg Med Chem Lett. 2015;25:940-3 pubmed publisher
    The discovery of non-symmetric thienoimidazole-containing HCV NS5A inhibitors is described. The inhibitors herein reported display high potencies against both genotype 1a and 1b...
  77. Floreani A. Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2015;16:801-4 pubmed publisher
    The fixed dose combination of sofosbuvir and ledipasvir (SOF/LDV) has marked a new era for patients with chronic HCV because it is the first drug to be approved by the FDA that does not include peginterferon or ribavirin...
  78. Nabekura T, Kawasaki T, Kamiya Y, Uwai Y. Effects of Antiviral Drugs on Organic Anion Transport in Human Placental BeWo Cells. Antimicrob Agents Chemother. 2015;59:7666-70 pubmed publisher
    ..In the present study, we examined the effects of anti-hepatitis C virus (HCV) and anti-HIV drugs on organic anion transport in human placental BeWo cells...
  79. Park S, Seronello S, Mayer W, Ojcius D. Hepatitis C Virus Frameshift/Alternate Reading Frame Protein Suppresses Interferon Responses Mediated by Pattern Recognition Receptor Retinoic-Acid-Inducible Gene-I. PLoS ONE. 2016;11:e0158419 pubmed publisher
    b>Hepatitis C virus (HCV) actively evades host interferon (IFN) responses but the mechanisms of how it does so are not completely understood...
  80. Hashimoto Y, Yagi K, Kondoh M. Current progress in a second-generation claudin binder, anti-claudin antibody, for clinical applications. Drug Discov Today. 2016;21:1711-1718 pubmed publisher
    ..Some CLDNs are co-receptors for hepatitis C virus. Because CLDN-driven regulation of intercellular seals might be manipulated to enhance drug absorption, ..
  81. Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, et al. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. Ann Intern Med. 2017;166:9-17 pubmed publisher
    ..Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear.
  82. Llaneras J, Riveiro Barciela M, Buti M, Esteban R. Hepatitis C virus genotype 4: Genotype 1's little brother. J Viral Hepat. 2017;24:4-12 pubmed publisher
    Treatment for hepatitis C virus genotype 4 infection has undergone a major advance over the past 5 years with the emergence of direct-acting antiviral agents...
  83. Schaefer E, Meixiong J, Mark C, Deik A, Motola D, Fusco D, et al. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. World J Gastroenterol. 2016;22:9954-9965 pubmed publisher
    To characterize the role of apolipoprotein B100 (apoB100) in hepatitis C viral (HCV) infection...
  84. Itami S, Eguchi Y, Mizutani T, Aoki E, Ohgi T, Kuroda M, et al. Control of HCV Replication With iMIRs, a Novel Anti-RNAi Agent. Mol Ther Nucleic Acids. 2015;4:e219 pubmed publisher
    ..miR-122 is an important mediator of RNAi that is known to control hepatitis C virus (HCV) replication and is being investigated in clinical trials as a target for anti-HCV therapy...
  85. Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Kato K, et al. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis. 2017;49:1029-1035 pubmed publisher
    ..effectiveness and safety of sofosbuvir/ribavirin therapy for elderly patients with genotype 2-infected chronic hepatitis C (CHC) in Japan...
  86. Gentile I, Buonomo A, Scotto R, Zappulo E, Carriero C, Piccirillo M, et al. Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. In Vivo. 2017;31:695-700 pubmed
    ..A case-control study was conducted in 2 hospital wards in Naples. All anti-HCV-positive patients affected by HCC were considered as cases, while consecutive anti-HCV-positive patients without ..
  87. Puoti C, Elmo M, Ceccarelli D, Ditrinco M. Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer?. Eur J Intern Med. 2017;46:1-5 pubmed publisher
    ..issue of the non-alcoholic fatty liver disease (NAFLD), perhaps due to the fact that the newly discovered hepatitis C virus did attract a paramount interest of hepatologists and researchers...
  88. Janda M, Mergenhagen K. The Effect of Psychosocial Factors on Success Rates of Hepatitis C Treatment. Psychosomatics. 2017;58:624-632 pubmed publisher
    ..which psychosocial factors interfere with patients reaching sustained virologic response (SVR), a marker for hepatitis C virus eradication. A retrospective chart review was performed between January 6, 2015 and February 24, 2016...
  89. Enciso Vargas M, Ruíz Madrigal B, Muñoz Valle J, Morales Balderas O, Hernández Nazara Z, Martínez López E, et al. Association of -319 C/T and +49 A/G polymorphisms of CTLA-4 gene in patients with hepatitis C virus infection. Med Clin (Barc). 2018;150:251-256 pubmed publisher
    ..modify the ability to control T lymphocyte proliferation, and promote the persistence or elimination of the hepatitis C virus (HCV)...
  90. Tsuda S. Laparoscopic repair of complicated umbilical hernia with Strattice Laparoscopicâ„¢ reconstructive tissue matrix. Int J Surg Case Rep. 2014;5:1167-9 pubmed publisher
    ..The patient had multiple comorbidities, including obesity, hepatitis C, endocarditis secondary to IV drug use, tobacco smoking, bilateral inguinal hernia, and recurrent umbilical ..
  91. Schueller F, Roy S, Vucur M, Trautwein C, Luedde T, Roderburg C. The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. Int J Mol Sci. 2018;19: pubmed publisher
    ..Despite epochal progress in the treatment of hepatitis C virus infections, pharmacological treatment strategies for most liver diseases are still limited and new targets ..
  92. Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, et al. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study. Clin Res Hepatol Gastroenterol. 2015;39:443-50 pubmed publisher
    ..triple therapy, respectively, was predictive of sustained virological response (SVR) in patients with hepatitis C virus (HCV) infection and to study the relevance of this measurement to early diagnose drug resistance...